Cell Medica bags €68,8 in Series C
British Cell Medica has closed a 60£ (€68,8m) Series C financing to advance its pipeline of virus-specific Natural Killer T (NKT) cells in oncology and viral infection.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Avantium raised €103m in oversubscribed IPO
According to main investor Sofinnova Partners, the Euronext IPO of Avantium, the front runner in renewable chemistry, was oversubscribed multiple times resulting in a market capitalisation of €277m.
NSCLC: Transgene launches cancer combo tests
Transgene has started Phase II efficacy testing of its therapeutic cancer vaccine TG4010 and Bristol-Myers Squibbs checkpoint inhibitor Opdivo (nivolumab) in non-squamous non-small cell lung cancer (NSCLC).
Allogenic stem cell transplant safe in heart infarction patients
Belgian cell therapeutics specialist TiGenix NV announced positive top-line one-year results from its CAREMI stem cell study in acute myocardial infarction.
Pharnext partners with Galapagos
Neurodegeneration specialist Pharnext SA and autoimmune disease expert Galapagos NV have inked an R&D contract in order to expand Pharnexts pleotherapy approach to new indications.
BerGenBio plans IPO and partners with MSD
Norwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Mercks PD-1 inhibitor pembrolizumab in lung cancer patients.
Next Big Thing in insurance: Digitalising Health
To date, insurance business models have always been based on damage control, but that paradigm is changing. Some insurers are now trying to hedge bets by motivating customers to get healthier and track that progress with the help of technology. Critics are concerned about data protection issues, and see this as a first step towards individualised premiums that will erode the principle of solidarity. What are the potential upsides and downsides for customers and societies?
Breath Therapeutics cashes in €43,5m
Inhaled lung therapeutics specialist Breath Therapeutics Holding BV closed a Series A financing led by Gimv and Sofinnova.
PwC reports high productivity of UK Life Sciences
The UKs Life Sciences sector is more than twice as productive as the UK average, says a new analyst report. However, it doesn’t come close to the productivity in Switzerland or other leading life sciences clusters.
Roche restarts pivotal Gantenerumab tests
MorphoSys AG has announced that its partner Roche plans to start two further pivotal Phase III studies with its licensed Alzheimers antibody Gantenerumab.